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Abstract
Background: Enzootic nasal tumor virus (ENTV-1) is an ovine betaretrovirus that has been linked to enzootic nasal
adenocarcinoma (ENA), a contagious tumor of the ethmoid turbinates of sheep. Transmission experiments
performed using virus isolated from cell free nasal tumor homogenates suggest that ENTV-1 is the causative agent
of ENA; however, this etiological relationship has not been conclusively proven due to the fact that the virus
cannot be propagated in vitro nor is there an infectious molecular clone of the virus.
Methods: Here we report construction of a molecular clone of ENTV-1 and demonstrate that transfection of this
molecular clone into HEK 293T cells produces mature virus particles.
Results: Analysis of recombinant virus particles derived from the initial molecular clone revealed a defect in the
proteolytic processing of Gag; however, this defect could be corrected by co-expression of the Gag-Pro-Pol
polyprotein from the highly related Jaagsiekte sheep retrovirus (JSRV) suggesting that the polyprotein cleavage sites
in the ENTV-1 molecular clone were functional. Mutagenesis of the molecular clone to correct amino acid variants
identified within the pro gene did not restore proteolytic processing; whereas deletion of one proline residue from
a polyproline tract located in variable region 1 (VR1) of the matrix resulted in production of CA protein of the
mature (cleaved) size strongly suggesting that normal virion morphogenesis and polyprotein cleavage took place.
Finally, electron microscopy revealed the presence of spherical virus particles with an eccentric capsid and an
average diameter of about 100 nm.
Conclusion: In summary, we have constructed the first molecular clone of ENTV-1 from which mature virus
particles can be produced. Future experiments using virus produced from this molecular clone can now be
conducted to fulfill Koch’s postulates and demonstrate that ENTV-1 is necessary and sufficient to induce ENA in
sheep.
Background
Protease-mediated processing of the Gag-Pro-Pol polypro-
tein is an essential step in the replication of retroviruses
[1]. The protease is activated concurrent with egress, or
shortly thereafter, at which time it is released from the
polyprotein via an autocatalytic reaction followed by pro-
teolytic processing of the remainder of the polyprotein [2].
The mechanism or trigger for activation of retroviral pro-
teases is unclear. Strict regulation of the protease is re-
quired to prevent premature activation, which would
inhibit virus assembly, budding and infectivity [3–6]. This
is especially important for betaretroviruses as the core
assembles within an intracellular compartment before
transport to the plasma membrane and release [2]. Several
studies have demonstrated that protein conformation/
dimerization [4, 7–9] and oxidation [10, 11] play an inte-
gral role in protease activation, but activation of ovine
betaretrovirus proteolytic processing has not been studied.
Inactive protease is detrimental to retroviral replica-
tion because in the absence of protease processing the
virion will not convert to the mature metastable con-
formation required for the virus to become infectious.
Indeed, there is a class of antiretroviral drugs designed
to specifically inhibit the protease and consequently in-
hibit virus replication [12, 13].
Enzootic nasal tumor virus (ENTV)-1 is an ovine
betaretrovirus that is associated with enzootic nasal
adenocarcinoma (ENA), a nasal tumor of sheep [14].
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Experiments showing transmission of ENA to a healthy
lamb by inoculation with cell-free ENA tumor homogen-
ate containing ENTV-1 antigens suggested that ENTV-1
is the causative agent of ENA, but did not completely
fulfil Koch’s postulates [14]. A factor limiting these ex-
periments is an inability to produce high titer virus from
cell culture since the virus cannot be propagated in vitro.
In the study presented here, we sought to resolve this
issue by constructing a molecular clone from which in-
fectious ENTV-1 could be generated. Transfection of
HEK 293T cells with the ENTV-1 molecular clone led to
the production of virus particles, but processing of the
Gag polyprotein was not observed. The protease could
not be activated by treatment with a reducing agent but
could be complemented with the JSRV Gag-Pro-Pol
polyprotein producing virus particles with fully proc-
essed Gag. Mutagenesis of non-conserved amino acids
within the protease domain failed to restore Gag poly-
protein processing; however, removal of an additional
proline residue from a polyproline tract in the matrix
protein resulted in the production of fully mature virus
particles. This is the first report demonstrating that
ENTV-1 can be produced from a molecular clone pro-
viding the foundation for further studies investigating
the pathogenesis and determinants of tissue tropism of
this poorly understood virus.
Methods
Cloning and vector construction
Two overlapping fragments comprising the ENTV-1
genome were amplified from genomic DNA (Genbank
accession number FJ744146) isolated from an ENA sam-
ple using PfuUltra II Fusion HS DNA Polymerase (Agi-
lent Technologies, Missisauga, Ontario, Canada) and the
E5F/E5R and E3F/E3R primer pairs (Table 1) for the 5’
fragment and the 3’ fragment, respectively. PCR prod-
ucts were cloned using the TOPO TA cloning kit (Life
Technologies). Subsequently, the cytomegalovirus
(CMV) promoter was amplified from the pcDNA3.1
plasmid and fused to the 5’ ENTV-1 genome fragment
at the 5’ border of the R region using overlap extension
PCR (using primers CMVF, RCMVR, E5F and EGagR,
Table 1). The CMV-RU5 fusion fragment was inserted
into the 5’ ENTV-1 fragment using XbaI and BsrGI re-
striction sites. The 5’ fragment was excised using XbaI
and MmeI and the 3’ fragment was excised using NotI
and MmeI and both were ligated into
XbaI and NotI digested low copy number plasmid,
pLG338/30 (provided by Dr. Ronald C. Montelaro
through the AIDS Reagent Program, Bethesda, Maryland,
USA) [15]. Plasmids containing ENTV-1 genome frag-
ments were prone to recombination in E. coli and thus
were incubated at a reduced temperature (30 °C). The
JSRV molecular clone, pCMVJSRV21 [16], and the JSRV
Gag-Pro-Pol polyprotein expression vector, pCMVGPP-
MX-4CTE [17], were kind gifts from Dr. Massimo
Palmarini, University of Glasgow, Scotland.
Amino acid changes were introduced into the ENTV-1
molecular clone (Fig. 3b) using a modified site-directed
mutagenesis protocol as outlined by Wang et al. [18]
using the primer pairs (EproS199P F/R, EproT202M F/R
and EproT289I F/R) in Table 1 and the KOD Hot Start
DNA Polymerase kit (Novagen) according to the manu-
facturer’s instructions. Briefly, mutagenesis was per-
formed with two separate amplification reactions
containing either forward or reverse primers to amplify
the molecular clone plasmid for three rounds. The two
single-primer PCR products were combined in one tube
and amplified for a further 14 rounds. Methylated paren-
tal plasmid DNA was digested with DpnI before trans-
formation into competent GT116 (InvivoGen) E. coli.
RT-PCR
Total RNA was extracted from HEK 293T cells trans-
fected with either pCMVENTV-1 or pCMVJSRV21 and
cDNA was generated using the JEenvR primer (Table 1)
and the SuperScript II Reverse Transcriptase kit (Life
Technologies) according to manufacturer instructions. A
PCR product representing the spliced envelope tran-
script from JSRV (393 bp) and ENTV (384 bp) were
amplified from the cDNA using Platinum PCR
Table 1 Primers used in cloning and mutagenesis



















Primers utilized in the generation and mutagenesis of the molecular clone and
in screening for ENTV-1 transcripts derived from the molecular clone are listed
along with the corresponding sequences on the right (5’ to 3’)
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SuperMix (Life Technologies) and the JU5F/JenvR and
EU5F/EenvR primer pairs (sequences shown in Table 1
and genome location shown in Fig. 1a) to amplify JSRV
and ENTV-1 mRNA transcripts, respectively.
Cell lines and virus production
HEK 293T, GSM-T (a goat synovial membrane cell line
immortalized with telomerase expression; a kind gift
from Dr. Yahia Chebloune, Université Joseph Fourier),
SSF (sheep skin fibroblasts) and ONTC (ovine nasal
tumor cell line) [19] cells were grown in Dulbecco’s
minimum essential medium (DMEM) supplemented
with 10% fetal bovine serum and 2 mM glutamine at
37 °C under 5% CO2. To produce primary sheep respira-
tory cells, fetal lung and nasal tissue was diced with a
scalpel and subsequently dispersed by passage through a
20-gauge needle. Non-adherent cells were removed 72 h
after plating and the remaining adherent cells were
treated with trypsin for 3 minutes to remove fibroblast
cells and enrich for epithelial cells. The cells were propa-
gated in epithelial specific medium (KSFM; Gibco) for
three to four passages before transfection.
For virus production, 5 × 106 HEK 293T cells plated
on 10 cm dishes were transfected with either the JSRV
or ENTV molecular clone using the calcium phosphate
co-precipitation method and medium was replaced after
Fig. 1 Lack of Gag-Pro-Pol polyprotein processing in virions derived from the original ENTV-1 molecular clone. a The ENTV-1 genome was amplified
from genomic DNA isolated from an ENA tumor (ENTV-1NA4) in two overlapping fragments. The CMV promoter was fused to the 5’ ENTV-1 genome
at the 5’ border of the R region in an intermediate fragment by overlap extension PCR and was introduced into the 5’ genome fragment via the BsrGI
restriction site. The fragments were ligated together at the MmeI restriction site and the ENTV-1 molecular clone was generated by ligation into the
pLG338/30 plasmid. b Singly spliced transcripts coding for the envelope protein were detected in RNA extracted from HEK 293T cells transfected with
the ENTV-1 or JSRV molecular clone and the resulting PCR products are shown. A schematic outlining this strategy and the location of the primers
(arrows) used in the RT-PCR is shown above. M indicates the lanes containing a 100 bp DNA ladder (Life Technologies). c Immunoblot analysis of
capsid protein in the lysates of concentrated virus particles derived from the indicated molecular clones after transfection of HEK 293T
cells. M indicates the lane containing the molecular weight marker and lanes labelled ECa contain bacterially expressed and purified ENTV-1 capsid
protein. The black arrows indicate unprocessed Gag at 78 kDa and the red arrows indicate processed capsid at 26 kDa. The dashes on the right hand
side demarcate unprocessed forms of Gag
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16 h with 5 ml of fresh medium. The virus-containing
medium was harvested 48 h later, passed through a
0.45 μm filter and pelleted by ultracentrifugation
through a 20% sucrose cushion in a SW32 Ti rotor
(Beckman Coulter Canada, Mississauga, Ontario,
Canada) at 60,000 × g for 2 h at 4 °C. The viral pellet
was suspended in TNE buffer [16].
Western blot analysis
Western blotting was conducted as described previously
[20] using monoclonal antibodies specific for the enve-
lope protein of ovine betaretroviruses [21] (i.e., JSRV,
ENTV and enJSRV) and the capsid protein [22] (kindly
provided by Dr. Hung Fan, University of California,
Irvine).
Electron microscopy of ENTV- 1 particles
Five microliters of ENTV-1 virus purified through a 20%
sucrose cushion were aliquoted onto a glow discharged,
200 mesh, copper grid (Electron Microscopy Sciences),
with formvar and carbon coating. The droplet was
wicked off with filter paper after 30 s and the grid
floated on a droplet of 2% Uranyl Acetate for 10 s. The
sample was imaged in the FEI Tecnai G2 FEG (Micros-
copy Imaging Facility, University of Guelph) at 200 kV
and images collected with the Gatan 4 K bottom mount
CCD camera using the Gatan Digital Micrograph
software.
Results
The ENTV-1 molecular clone produces unprocessed
immature virions
ENTV-1 cannot be propagated in conventional cell cul-
ture systems, therefore it was necessary to generate a
molecular clone in order to produce virus for experi-
mental purposes and to show that ENTV-1 alone is suf-
ficient to induce nasal tumors in sheep. The full-length
ENTV-1 genome was amplified from genomic DNA ex-
tracted from ENA tumor tissue in two overlapping frag-
ments and cloned into a plasmid with the CMV
promoter fused to the 5’ end of the R region (Fig. 1a).
The 5’ U3 was replaced with a CMV promoter to pro-
mote high-level expression in human cells. The resulting
plasmid (pCMVENTV-1) was transfected into HEK
293T cells and after 48 h, RNA was extracted and sub-
jected to RT-PCR using a forward primer in the U5 re-
gion and a reverse primer in the signal peptide region of
env (see black arrows in Fig. 1a) producing a band at ap-
proximately 384 bp (Fig. 1b). This band represented
spliced ENTV-1 envelope transcripts and demonstrated
that the molecular clone could support transcription of
viral genes. The JSRV molecular clone was analysed in
parallel and showed a PCR product of the predicted
393 bp (Fig. 1b). Recombinant ENTV-1 and JSRV
particles produced in HEK 293T and concentrated by
ultracentrifugation were subjected to SDS-PAGE separ-
ation and immunoblot analysis using a monoclonal anti-
body against the JSRV capsid, which cross-reacts with
the ENTV-1 capsid. A protein of 26 kDa was detected in
the lane containing JSRV lysate (Fig. 1c, lane 2) as well
as in the lane containing bacterially expressed ENTV-1
capsid (ECa) protein (Fig. 1c, lane 4). However, this
26 kDa protein was absent in the ENTV-1 molecular
clone (Fig. 1c, lane 3) and instead, a protein of approxi-
mately 78 kDa, which is the expected size of the unpro-
cessed Gag polyprotein, was detected. Taken together,
these results suggest that the ENTV-1 molecular clone
is able to direct production of virus particles but that
there is a defect in proteolytic processing.
The JSRV Gag-Pro-Pol polyprotein can complement and
correct the processing defect of the ENTV-1 molecular
clone
The mechanism responsible for initiating protease pro-
cessing and maturation is not well understood. To deter-
mine whether the ENTV-1 genome and envelope
protein contribute to the processing defect, the JSRV
Gag-Pro-Pol polyprotein alone (pCMVGPP-MX-4CTE)
was supplied in trans to allow co-assembly with the
ENTV-1 polyprotein and packaging of the ENTV-1 gen-
ome thereby producing chimeric virus particles. HEK
293T cells were co-transfected with pCMVENTV-1 and
pCMVGPP-MX-4CTE and virus purified from the
supernatant was analyzed by Western blot using an anti-
body specific for the JSRV capsid (JCa). Virus from cells
transfected with either the JSRV molecular clone (Fig. 2a,
lane 2) or the ENTV-1 molecular clone (Fig. 2a, lane 3)
showed banding patterns identical to those observed
previously in Fig. 1. A single protein migrating at a mo-
lecular weight of 26 kDa was observed in virus particles
produced from cells co-transfected with pCMVENTV-1
and pCMVGPP-MX-4CTE (Fig. 2a, lane 4) indicating
that JSRV Gag-Pro-Pol can be packaged into the ENVT-
1 virus and complement ENTV-1 processing defect.
Since Gag polyprotein expression levels from the
pCMVGPP-MX-4CTE plasmid were much greater than
from either of the two molecular clones, we performed
an experiment to determine the dose dependence of this
complementation. Dose dependency experiments were
performed with JSRV Gag-Pro-Pol maintained at a con-
sistent level and ENTV-1 progressively increased
(Fig. 2b) as well as the inverse (Fig. 2c). When ENTV-1
was supplied in excess, a band was detected at both
26 kDa and 78 kDa (Fig. 2b lane 7 and 8 and 2C lane 3).
Proteins of approximately 62, 57, 52 and 40 kDa in a
banding pattern reminiscent of partially processed Gag
[14, 23] were also detected (Fig. 2b, lane 8). Since the
JSRV Gag-Pro-Pol expression construct lacks a
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packaging signal, the virions produced in these experi-
ments were presumed to have assembled around the
ENTV-1 genome, indicating that the genomic RNA de-
rived from the ENTV-1 molecular clone is not respon-
sible for the processing defect and that the polyprotein
cleavage sites are intact.
Mutagenesis of the ENTV-1 protease to resemble the JSRV
protease does not restore proteolytic processing
Since the ENTV-1 molecular clone was generated from
two large overlapping PCR products, we investigated
whether mutations might have been acquired during the
amplification step, which could have affected protease ac-
tivity. The ENTV-1 molecular clone, pCMVENTV-1, was
sequenced in its entirety using primers described previ-
ously [19]. The protease sequence of pCMVENTV-1 was
then compared to that of all North American ENTV-1 iso-
lates, including the ENTV-1NA4 isolate from which
pCMVENTV-1 was derived, the European ENTV-1 isolate,
ENTV-2 from goats and finally, JSRV using MEGA5 soft-
ware (Fig. 3a). A proline to serine change at position 199
unique to the pCMVENTV-1 protease was identified (out-
lined with a red box, Fig. 3a). This amino acid difference
was located in the peptidase domain, 18 amino acids
downstream from the catalytic aspartate residue, based
upon sequence similarity and alignment with MPMV pro-
tease [24]. This mutation was of interest because prolines
may influence secondary structure due to their “kinked”
conformation [25, 26], and none of the available ovine
betaretrovirus sequences possess a serine residue at this
position. Two other sites of amino acid variability were
noted, one in the peptidase domain (T versus M at position
202, outlined with a blue box in Fig. 4a) and the other in
the G-patch domain (I versus T at position 289, outlined
with a blue box highlighted in Fig. 3a). It should be noted
that there was one additional amino acid difference that
followed this pattern at position 147, but since it was local-
ized to the dUTPase region of the polyprotein it was not
included as a candidate for mutagenesis. Site-directed mu-
tagenesis was performed on pCMVENTV-1 to first change
the serine at position 199 to a proline (pCMVENTV-
1S199P). Subsequent amino acid changes were introduced
into pCMVENTV-1S199P to produce pCMVENTV-
1S199P, T202M and pCMVENTV-1S199P, T289I, which
resembled 9/15 of the ovine betaretrovirus sequences ana-
lyzed. Virus was generated from the modified molecular
clones and analyzed by immunoblot for capsid protein ex-
pression (Fig. 3b). Despite mutating the protease of the
ENTV-1 molecular clone to resemble that of known infec-
tious viruses, there was no change in the processing defect
of any of the mutant viruses as only unprocessed Gag
could be detected (Fig. 3b). These results suggest that ei-
ther all three amino acid variants within the protease need
to be corrected or amino acid variants outside of the prote-
ase are contributing to the processing defect.
Deletion of a proline residue from the polyproline tract in
the matrix protein results in production of fully mature
ENTV-1 virions
In searching for regions within Gag that might be con-
tributing to the processing defect, it was curious that
Fig. 2 Dose dependent rescue of ENTV-1 polyprotein processing
defect by complementation with JSRV Gag-Pro-Pol. a Capsid protein
immunoblot analysis of virus particles obtained from HEK 293T cells
co-transfected with the ENTV-1 molecular clone and the JSRV Gag-Pro-
Pol expression vector (ENTV-1/J-GP) showing protease processing of
the Gag polyprotein (lane 4). Virus derived from transfection of the
JSRV (lane 2) and ENTV (lanes 3) molecular clones. The dosage
dependence of polyprotein processing was evaluated by co-
transfection of consistent amounts of JSRV Gag-Pro-Pol (0.5ug)
with increasing amounts of ENTV-1 (1 to 10 μg) (b) as well as
consistent amounts of ENTV-1 (5 μg) and increasing amounts of
JSRV Gag-Pro-Pol (0.5 to 5 μg) (c). M indicates the lane containing the
molecular weight marker. The black arrows indicate unprocessed Gag
at 78 kDa and the red arrows indicate processed Capsid at 26 kDa
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four of the ten full-length sequences we previously ob-
tained for ENTV-1 isolates from North America pos-
sessed an additional proline residue in the polyproline
tract of the matrix subunit of Gag (Fig. 4a), just up-
stream of a putative cleavage site [19]. We hypothesized
that this additional proline could introduce a structural
change in the protein that might reduce cleavage effi-
ciency and/or alter the conformation of the protease
such that it was no longer able to dimerize and become
active. To investigate this possibility, the molecular clone
containing the S199P correction (pCMVENTV-1S199P),
was mutated to restore the four amino acid long
Fig. 3 Mutagenesis of the ENTV-1 protease to resemble the JSRV protease does not restore proteolytic processing. a ClustalW alignment of the
predicted amino acid sequence of the protease from the ENTV-1 molecular clone with that of all 10 ENTV-1 isolates from North America (ENTV-
1NA, see Table 1 [19] for accession numbers), ENTV-1OVC (accession number KC189895) [41], ENTV-2 (accession number NC 004994), JSRV (accession
number AF105220) and an endogenous JSRV (enJS56A1, accession number AF153615). Dots indicate identical amino acids. The black arrow marks the
catalytic amino acid, shown in red. The red box highlights the S199P mutation found only in the original ENTV-1 molecular clone. The
blue boxes highlight amino acids where the ENTV-1 molecular clone is more similar to ENTV-1NA4, from which it was derived, and the
three other isolates that were obtained from the same farm as ENTV-1NA4: ENTV-1NA2, ENTV-1NA3, and ENTV-1NA5. b Capsid protein
immunoblot analysis of lysates from concentrated viruses derived from the ENTV-1 molecular clone containing the designated amino acid
changes in the protease domain. M indicates the lane containing the molecular weight marker and lanes labelled as ECa contain bacterially expressed
and purified ENTV-1 capsid protein. The black arrow indicates unprocessed Gag at 78 kDa and the red arrow indicates processed Capsid at 26 kDa
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polyproline tract in the Matrix protein. Indeed, the
ENTV-1 molecular clone possessing a polyproline tract
comprised of four consecutive proline residues
(pCMVENTV-1-S199PGagΔP) resulted in the produc-
tion of mature virions containing fully processed Gag
(Fig. 4b). Transmission electron microscopy of a concen-
trated virus preparation detected spherical structures
with an electron-dense, eccentric core, consistent with
type B retroviruses (Fig. 4c, d), whereas only unstructured
aggregates were found within the mock-transfected con-
trol (Fig. 4e). The average overall diameter of the struc-
tures (180 nm) is compatible with the predicted size of
betaretrovirus particles [27].
Discussion
ENA is a relatively common disease of sheep, particu-
larly in North America [19, 28]. Despite this, little is
known about the pathogenesis of the disease, including
confirmation of ENTV-1 as the etiologic agent. Much of
what is known about ENA and ENTV-1 is inferred from
studies on OPA and JSRV. We endeavoured to address
this problem and build upon our previous transmission
experiments involving cell-free tumor homogenate by
constructing a molecular clone of ENTV-1 from which
virus could be generated for in vivo infection experi-
ments. Failure of the original molecular clone to produce
mature virions comprised of fully processed viral pro-
teins presented a unique impediment to these experi-
ments, but ultimately revealed important biological
insights about ENTV-1.
Initially we thought that the defect in Gag polyprotein
processing could be due to the requirement for a host
cell protein found only in sheep cells or alternatively,
due to the presence a restriction factor in human cells
that inhibited maturation of ENTV-1 virions. To address
this possibility, we attempted to produce recombinant
ENTV-1 virions in both primary and continuous cell
lines from sheep and goat; however, these cells were ex-
tremely resistant to transfection and did not yield suffi-
cient amounts of virus for analysis, even after
ultracentrifugation of virus-containing supernatant (data
not shown). Indeed, it was difficult to observe ENTV-1
virions produced in HEK 293T cells in situations where
the transfection efficiency was suboptimal; suggesting
that virus production by this method is extremely ineffi-
cient. Since JSRV particles produced from HEK 293T
cells are capable of polyprotein processing and the se-
quence identity between JSRV and ENTV-1 is relatively
high, we concluded that it was unlikely that the defect in
Gag polyprotein processing observed in virus particles
produced from the ENTV-1 molecular clone was due to
the absence of a critical host cell factor in the producer
cells.
Co-transfection of the JSRV Gag-Pro-Pol expression
vector with the ENTV-1 molecular clone generated vi-
rions with fully processed Gag (Fig. 2a). The antibody
used in this experiment does not distinguish between
JSRV and ENTV-1 capsid proteins so it was not possible
to determine whether rescue of polyprotein processing
was due to processing of ENTV-1 Gag by the JSRV pro-
tease or displacement of the ENTV-1 polyprotein by the
Fig. 4 Deletion of a proline residue from the polyproline tract in the
matrix protein results in production of fully processed ENTV-1 virions.
a ClustalW alignment of variable region 1 (VR1) of the matrix protein
from a European isolate of ENTV-1 (ENTV-1EU, accession number NC
007015), all ten ENTV-1 isolates from North America (ENTV-1NA, see
Table 1 [19] for accession numbers), ENTV-2 (accession number NC
004994), JSRV (accession number AF105220) and an endogenous
JSRV (enJS56A1, accession number AF153615). Dots indicate identical
amino acids and dashes indicate deletions. Nonconserved proline
residues are highlighted in red. b Immunoblot analysis of capsid in
cell lysates or concentrated virus particles derived from the JSRV
molecular clone (pCMVJSRV21), the ENTV-1 molecular clone with the
S199P mutation (pCMVENTV-1S199P), and the final version of the
ENTV-1 molecular clone with the S199P and the delta Pro mutation
(pCMVENTV-1S199PGagΔP) after transfection of HEK 293 T cells. M
indicates the lane containing the molecular weight marker and lanes
labelled as ECa contain bacterially expressed and purified ENTV-1
capsid protein. c and d Two representative examples of transmission
electron microscope analysis of recombinant ENTV-1 particles. e
Transmission electron microscope analysis of control grid coated
with concentrated cell-free supernatant derived from mock
transfected cells
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JSRV polyprotein. The JSRV Gag-Pro-Pol expression
vector contains additional elements (e.g., MPMV CTE
and SV40 polyA) [17] that promote much higher expres-
sion of Gag-Pro-Pol than the molecular clone so direct
comparisons are not possible. Expression level differ-
ences were taken into account in the dosage response
co-transfection experiments (Fig. 2b and c) in order to
encourage heterologous Gag polyprotein co-packaging
(ie. generation of virions with polyproteins from both
JSRV and ENTV-1) [29]. Incomplete rescue of process-
ing, observed as partially processed Gag in lane 7 and 8
of Fig. 2b, indicates that the JSRV protease is processing
the ENTV-1 polyprotein in trans in these virions but
that there is a limit to which the JSRV protease can per-
form this function. Therefore, since the ENTV-1 poly-
proteins can be processed by the JSRV protease we
concluded that the processing defect was due to a lack
of ENTV-1 protease activity.
Interestingly, mutation of the pCMVENTV-1 protease
to match that of ENTV-1NA4, the sequence from which
it was derived, failed to rescue the processing defect.
This was unexpected considering that the ENTV-1NA4
sequence was derived from nasal tumor tissue isolated
from a sheep with ENA. Although only fully processed
Gag was observed in virions purified from the ENTV-
1NA4 tumor or any of the other ENTV-1NA tumors
[14], a processing defect could exist outside the context
of transformed sheep cells. Since ENTV-1OVC was ex-
tracted from a tumor transmitted by cell-free tumor
homogenate [14], it was assumed that this sequence rep-
resented a replication-competent, infectious ENTV-1. It
should be noted that homogenates from the ENTV-
1OVC tumor contained unprocessed and partially proc-
essed Gag proteins which were thought to represent
naked cores released from the cytoplasm of tumor cells
due to mechanical disruption [14]. It is possible that the
processing defect observed in virions derived from the
initial ENTV-1 molecular clone may be reflective of the
phenotype of at least some circulating exogenous
ENTV-1 particles. If that were the case, these virions
would not be infectious unless complemented with an
active protease, perhaps from endogenous betaretrovirus
sequences [30]. Expression of the endogenous ovine
betaretroviruses is localized primarily to tissues of the
reproductive tract [31]; however, transcripts have been
detected in other tissues such as the lung [32]. Human
endogenous retrovirus (HERV) sequences are upregu-
lated in neoplastic tissues due to genomic instability and
epigenetic changes during transformation [33–35] and a
similar phenomenon occurs in HIV-infected cells [36].
Furthermore, HERV-K (a member of the Betaretrovirus
genus) Gag can co-assemble and co-package with HIV-1
Gag [37]. Similarly, it has been shown that endogenous
JSRV Gag can co-assemble with exogenous JSRV Gag
and, in the presence of a particular mutation (R21W),
restrict the release of exogenous JSRV particles in a
transdominant fashion [38, 39]. The high degree of simi-
larity shared between ENTV-1, JSRV and endogenous
ovine betaretroviruses [19] suggests that since ENTV-1
can co-assemble with JSRV, it can likely also co-
assemble with at least some of the endogenous ovine
betaretrovirus Gag proteins. Therefore, it is conceivable
that infection of sheep cells with ENTV-1 and subse-
quent transformation results in upregulation of en-
dogenous betaretrovirus transcription, which in turn
supplies polyproteins with active protease for co-
packaging.
Since modification of the protease sequence of the de-
fective molecular clone to match that of ENTV-1OVC
failed to restore Gag polyprotein processing, we investi-
gated sequence differences outside of the pro reading
frame that might be responsible for the defect. In HIV,
regions upstream of the protease play a critical role in
protease activation by influencing dimerization of the
protease domain in the precursor [40], which is require-
ment for activation [41]. Of the ten ENTV-1 genomes
we previously sequenced, four possessed a polyproline
motif comprised of five consecutive prolines within the
matrix region of Gag, which differed from the four con-
secutive prolines that comprised this motif in the other
six ENTV-1 genomes, as well as in the genome of an
ENTV-1 virus isolated in the UK. Despite being located
in one of three variable regions in the ovine betaretro-
virus genome, this polyproline motif is conserved within
virus families and is consistently comprised of seven
consecutive prolines in the case of JSRV and six con-
secutive prolines in the case of ENTV-2. Interestingly,
this polyproline motif is absent from endogenous ver-
sions of JSRV [42]. Since proline residues are known to
introduce kinks in protein structures we theorized that
the additional proline residue in the Gag-Pro-Pol poly-
protein might prevent the protease from folding cor-
rectly, precluding dimerization and activation. Indeed,
mutation of the molecular clone to restore the four
amino acid long polyproline motif resulted in the recov-
ery of mature virions containing fully processed Gag.
Exactly why the addition of a proline residue to this
motif had such a detrimental effect on polyprotein pro-
cessing is not known; however, one might surmise that it
could contribute to conformational changes in the poly-
protein that alter protein-protein interactions, or as in
the case of the Vpx protein of HIV-2, may reduce trans-
lation efficiency. Vpx proteins of the HIV-2/SIVsmm/
SIVmac group encode a highly conserved polyproline
motif (PPM) consisting of a hepta-proline stretch in the
C-terminal region [43, 44]. Recently, the PPM in HIV-2
Vpx was shown to be critical for its efficient expression
in both eukaryotic and prokaryotic systems and this
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effect is determined by the context of PPM amino acid
sequences, not the nucleotide sequences [45]. Import-
antly, the number and position of consecutive prolines
in this PPM were important for Vpx expression. PPMs
are found in a large number of eukaryotic and prokary-
otic proteins as well as in a wide range of human DNA
and RNA viruses including herpesviruses, adenoviruses,
and hepatitis viruses. However, whether these PPMs are
responsible for efficient expression of the PPM-
containing proteins or play some other as yet unidenti-
fied role in protein function is not yet known.
Conclusions
In summary, we have constructed a molecular clone of
ENTV-1 that is capable of directing the production of
mature virus particles containing fully processed Gag-
Pol. As there are no cell lines that support replication of
ENTV-1, experiments are underway to confirm the in-
fectious nature of virus produced from this molecular
clone in newborn lambs. Construction of an ENTV-1
molecular clone will allow for the first time detailed in-
vestigations into the mechanisms contributing to the
pathogenesis and tissue tropism of this poorly under-
stood virus.
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